So far, Vuity is still the only one available, but there are more on the horizon. Orasis Pharmaceuticals announced results from its phase 2b study, which were presented at ASCRS last week.
The trial results showed that CSF-1 (pilocarpine HCl 0.4%) met its primary endpoint, with 47% of participants in the CSF-1 group achieving a 3-line or more gain in DCNVA 1 hour post treatment on Day 15 compared with 16% in the vehicle group.
Additionally, the trial met its secondary endpoint, with 80% of participants in the CSF-1 group achieving a 2-line or more gain in DCNVA compared with 43% in the vehicle group.
What are the highlights on CSF-1?
CSF-1 is preservative-free 0.4% pilocarpine formulated in a proprietary vehicle. The dosing is twice daily.
When will it be available?
It's looking like CSF-1 will be commercially available in 2023. The company plans to submit an NDA later this year.